>India’s law sets a higher bar for protection than in some other countries, limiting the ability of companies to get patents for new versions of drugs whose active ingredients were previously known unless they can show significant therapeutic benefit.

It's not ignoring patents, it's setting a high bar for them. You can't rehash old medicine and patent them.